Effect of the JAK Inhibitor Baricitinib on Cytokine Production and Bone Properties in a Mouse Model of Accelerated Aging.
Аннотация
Age-related osteoporosis is characterized by progressive loss of bone mass and deterioration of bone microarchitecture, leading to enhanced skeletal fragility. Cytokines regulate bone remodeling through distinct signaling pathways. Baricitinib, a selective JAK1/2 inhibitor effective in inflammatory disorders such as rheumatoid arthritis, suppresses cytokine signaling, but its role in age-related osteoporosis remains insufficiently defined. In our study a total of 60 eight-month-old female SAMP8 mice were randomized to receive baricitinib (10 mg/kg) or vehicle twice daily by oral gavage for six weeks. Bone outcomes were evaluated by high-resolution micro-computed tomography (µCT) and static histomorphometry. Intracellular cytokine production by splenocytes was determined via flow cytometry. We found that baricitinib substantially reduced T-cell cytokine production, decreasing IL-6, IL-17, IFN-γ, and IL-21 in CD4+ T cells and IL-6 in CD8+ T cells, accompanied by lower IFN-γ/IL-17 and IL-21/IL-6 ratios, respectively. µCT analyses showed no significant intergroup differences in BV/TV, whereas histomorphometry demonstrated higher BV/TV in the baricitinib group. Overall, baricitinib was found to effectively suppressed proinflammatory cytokines in aged SAMP8 mice but did not consistently enhance bone parameters, indicating reduced skeletal responsiveness during aging.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.